Under New CEO, GSK Will Leverage OTCs In Emerging Markets
This article was originally published in The Pink Sheet Daily
Executive Summary
Glaxo will look at opportunities to expand its nonprescription business, as OTC and other products have more long-term sales consistency than Rx drugs, North American Pharmaceuticals President Viehbacher says.
You may also be interested in...
GSK Acts On Cost Plan, Cuts Research Jobs
U.K. firm’s busy spring includes internal downsizing, external investments.
Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round
Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.